AbbVie (NYSE:ABBV) Stock Price Up 1.4% Following Analyst Upgrade

Posted by Francis Steltz on Jul 23rd, 2026

AbbVie Inc. (NYSE:ABBV – Get Free Report)’s share price was up 1.4% during trading on Thursday after Canaccord Genuity Group raised their price target on the stock from $273.00 to $282.00. Canaccord Genuity Group currently has a buy rating on the stock. AbbVie traded as high as $258.38 and last traded at $256.80. 4,410,052 shares were traded during trading, a decline of 38% from the average session volume of 7,082,242 shares. The stock had previously closed at $253.30.

Several other research firms have also commented on ABBV. HSBC reissued a “buy” rating and set a $300.00 price target on shares of AbbVie in a research report on Monday, July 6th. BMO Capital Markets increased their price objective on AbbVie from $258.00 to $300.00 and gave the company an “outperform” rating in a report on Monday, July 13th. Evercore set a $235.00 price objective on AbbVie in a research note on Friday, May 15th. JPMorgan Chase & Co. lifted their target price on AbbVie from $260.00 to $280.00 and gave the stock an “overweight” rating in a report on Thursday, July 9th. Finally, Wall Street Zen lowered AbbVie from a “strong-buy” rating to a “buy” rating in a research report on Sunday, July 5th. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $268.10.

View Our Latest Research Report on AbbVie

Institutional Trading of AbbVie

A number of hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. grew its stake in shares of AbbVie by 1.7% during the 4th quarter. Vanguard Group Inc. now owns 180,779,699 shares of the company’s stock worth $41,306,353,000 after purchasing an additional 3,032,438 shares during the period. State Street Corp lifted its stake in shares of AbbVie by 1.4% in the 4th quarter. State Street Corp now owns 80,940,931 shares of the company’s stock valued at $18,494,193,000 after purchasing an additional 1,119,274 shares during the period. Geode Capital Management LLC boosted its holdings in AbbVie by 10.4% during the fourth quarter. Geode Capital Management LLC now owns 44,629,980 shares of the company’s stock worth $10,179,099,000 after buying an additional 4,190,487 shares in the last quarter. Bank of America Corp DE boosted its holdings in AbbVie by 1.4% during the fourth quarter. Bank of America Corp DE now owns 25,824,399 shares of the company’s stock worth $5,900,617,000 after buying an additional 356,394 shares in the last quarter. Finally, Norges Bank acquired a new stake in AbbVie during the fourth quarter valued at $5,865,055,000. Hedge funds and other institutional investors own 70.23% of the company’s stock.

AbbVie Price Performance

The business’s fifty day simple moving average is $232.69 and its two-hundred day simple moving average is $222.41. The company has a market cap of $453.71 billion, a PE ratio of 126.50, a PEG ratio of 0.85 and a beta of 0.30.

AbbVie (NYSE:ABBV – Get Free Report) last posted its earnings results on Wednesday, April 29th. The company reported $2.65 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.59 by $0.06. AbbVie had a net margin of 5.79% and a negative return on equity of 576.45%. The business had revenue of $15 billion for the quarter, compared to analyst estimates of $14.72 billion. During the same period in the prior year, the company posted $2.46 EPS. The company’s revenue for the quarter was up 12.4% on a year-over-year basis. As a group, analysts predict that AbbVie Inc. will post 14.18 EPS for the current year.

AbbVie Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, August 14th. Shareholders of record on Wednesday, July 15th will be issued a $1.73 dividend. This represents a $6.92 annualized dividend and a yield of 2.7%. The ex-dividend date of this dividend is Wednesday, July 15th. AbbVie’s dividend payout ratio (DPR) is presently 340.89%.

AbbVie Company Profile

(Get Free Report)

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.